SEASTAR MEDICAL HOLDING CORP
ICUNASDAQTrading Snapshot
- Day Range
- โ
- 52-Week Range
- $0.76 โ $5.38
- Volume (shares)
- โ
- Avg Volume (shares)
- โ
- Shares Outstanding
- 4.4M
- Next Earnings
- โ
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $615,000
- P/E Ratio
- โ
- P/S Ratio
- 2.9x
- EPS (TTM)
- $-3.93
- Dividend Yield
- โ
SEASTAR MEDICAL HOLDING CORP
ICUFinancial history unavailable.
About SEASTAR MEDICAL HOLDING CORP
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.